List view / Grid view
31 July 2015 | By Victoria White
The EC has approved the use of Perjeta in combination with Herceptin and chemotherapy for use before surgery in patients with early stage breast cancer...
28 July 2015 | By Victoria White
Atezolizumab is poised to become a major bladder cancer therapy in the race for FDA approval, following its promising performance in recent Phase II trials...
13 July 2015 | By Victoria White
In the Phase II IMvigor 210 study, Roche’s atezolizumab shrank tumours in people with locally advanced or metastatic urothelial bladder cancer (UBC)...
2 July 2015 | By Victoria White
Evotec and Roche have provided an update on the initial results of the Phase IIb trial with Sembragiline for the treatment of Alzheimer's disease...
30 June 2015 | By Victoria White
Roche has announced positive results from two studies evaluating ocrelizumab compared with interferon beta-1a in people with relapsing multiple sclerosis...
29 June 2015 | By Victoria White
The CHMP has recommended that the EC approves the use of Perjeta for the neoadjuvant treatment of adult patients with HER2-positive early breast cancer...
23 June 2015 | By Victoria White
Roche has announced new data from the first study of the novel humanised bispecific antibody ACE910 (RG6013) in people with severe haemophilia A...
18 June 2015 | By Victoria White
Roche has been selected to provide HIV-1 viral load and early infant diagnostic technologies for the Global Fund...
10 June 2015 | By Victoria White
The FDA has granted Breakthrough Therapy designation status to Roche’s ACTEMRA/RoACTEMRA (tocilizumab) for systemic sclerosis (SSc)...
2 June 2015 | By Victoria White
Amgen and Roche are to collaborate on a study to evaluate talimogene laherparepvec in combination with atezolizumab in patients with cancer...
From today, clinicians in England and Wales will be able to prescribe Roche's Gazyvaro for eligible patients with chronic lymphocytic leukaemia (CLL) on the NHS.
1 June 2015 | By Victoria White
Results from a Phase III study show that Gazyvaro provided significant benefit for people with indolent non-Hodgkin’s lymphoma (NHL)...
1 June 2015 | By Victoria White
Roche has announced new results from the Phase II NeoSphere study that assessed a Perjeta regimen in people with HER2-positive early breast cancer...
14 May 2015 | By Victoria White
Roche has announced interim results from a global, randomised Phase II study (POPLAR) of MPDL3280A in people with previously treated NSCLC...
14 May 2015 | By Victoria White
Results from two pivotal studies have shown that alectinib shrank tumours in people with advanced ALK-positive (ALK+) non-small cell lung cancer (NSCLC)...
